Free Trial

Cresco Labs (OTCMKTS:CRLBF) Shares Gap Down - What's Next?

Cresco Labs logo with Medical background

Key Points

  • Cresco Labs Inc. shares opened at $1.00 after closing at $1.04, reflecting a gap down before market open.
  • Canaccord Genuity Group downgraded Cresco Labs from a "strong-buy" to a "moderate buy" rating.
  • Cresco Labs reported a quarterly revenue of $163.62 million, which surpassed analysts' expectations although they missed on EPS, posting ($0.05) compared to the consensus of ($0.04).
  • Looking to export and analyze Cresco Labs data? Unlock 5 Weeks of MarketBeat All Access for Just $5. Claim Your Limited-Time Discount.

Cresco Labs Inc. (OTCMKTS:CRLBF - Get Free Report) shares gapped down prior to trading on Wednesday . The stock had previously closed at $1.04, but opened at $1.00. Cresco Labs shares last traded at $1.09, with a volume of 311,335 shares.

Wall Street Analysts Forecast Growth

Separately, Canaccord Genuity Group cut shares of Cresco Labs from a "strong-buy" rating to a "moderate buy" rating in a research report on Tuesday, June 3rd.

Read Our Latest Research Report on CRLBF

Cresco Labs Trading Up 15.0%

The company has a quick ratio of 2.22, a current ratio of 3.10 and a debt-to-equity ratio of 1.33. The business's 50 day moving average is $0.61 and its 200-day moving average is $0.70. The firm has a market cap of $554.85 million, a P/E ratio of -8.69 and a beta of 1.42.

Cresco Labs (OTCMKTS:CRLBF - Get Free Report) last issued its quarterly earnings results on Thursday, August 7th. The company reported ($0.05) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.04) by ($0.01). The company had revenue of $163.62 million during the quarter, compared to the consensus estimate of $162.00 million. Cresco Labs had a negative return on equity of 11.77% and a negative net margin of 6.67%. As a group, analysts forecast that Cresco Labs Inc. will post -0.2 earnings per share for the current fiscal year.

Cresco Labs Company Profile

(Get Free Report)

Cresco Labs Inc, together with its subsidiaries, cultivates, manufactures, and sells retail and medical cannabis products in the United States. It provides cannabis in flowers, vape pens, live resins, disposable pens, and extracts under the Cresco brand; vape carts, vape pens, flower, popcorn, shake, pre-rolls, shorties, and concentrates under the High Supply brand; vapes and gummies under the Good News brand; vapes and edibles under the Wonder Wellness Co brand; and tinctures, capsules, salves, and sublingual oils under the Remedi brand.

Further Reading

Should You Invest $1,000 in Cresco Labs Right Now?

Before you consider Cresco Labs, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cresco Labs wasn't on the list.

While Cresco Labs currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Next Tech Boom: AI Robots Are Coming Sooner Than You Think!
Tech Stocks Stumble: Will Nvidia’s Report Spark a Rebound?
Follow the Money: 5 Stocks Institutions Are Buying NOW

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines